| abstract |
The invention relates to new uses of the dimerised form of lysozyme for the manufacture of a medicament for inhibiting biosynthesis of Tumor Necrosis Factor in animals and humans. The lysozyme dimer is in particular useful for the treatment and prophylaxis of diseases associated with excessively high levels of Tumor Necrosis Factor. The invention further relates to pharmaceutical formulations of the medicament according to the invention, namely injections comprising the dimerised form of lysozyme in amounts of 0,01-10 mg/ml, of an apyrogenic sterile composition comprising at least one physiologically acceptable solvent and at least one pharmaceutically approved preservative, as well as to tampons and antiseptive dressings impregnated with, and ointments or gels comprising an effective dose of the dimerised form of lysozyme for the prevention and/or treatment of sepsis and septic shock, especially of infected wounds. |